AMPLIFICATION AND OVEREXPRESSION OF THE PSMB5 GENE CONTRIBUTE TO BORTEZOMIB RESISTANCE IN RE-TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA

被引：0
|
作者：
Altavilla, Giuseppe [1 ]
Arrigo, Carmela [1 ]
Sauta, Maria Grazia [1 ]
Galletti, Giuseppe [1 ]
Gnani, Alessandro [1 ]
Pettineo, Giuseppe [1 ]
Buemi, Barbara [1 ]
Pitini, Vincenzo [1 ]
机构：
[1] Univ Messina, Human Pathol Dpt, Med Oncol Unit, I-98100 Messina, Italy
来源：
ANNALS OF ONCOLOGY | 2009年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：2
相关论文
共 43 条
  • [31] MAINTENANCE THERAPY vs RE-TREATMENT AT BIOCHEMICAL RELAPSE vs OBSERVATION IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) PATIENTS: RESULTS OF A PHASE II, RANDOMIZED STUDY
    Mina, R.
    Larocca, A.
    Belotti, A.
    Conticello, C.
    Monaco, F.
    Offidani, M.
    Ronconi, S.
    Marchetti, M.
    Ria, R.
    Conconi, A.
    Pescosta, N.
    Grasso, M.
    Capra, A.
    Zambello, R.
    Poggiu, M.
    Giuliani, N.
    Ballanti, S.
    Cellini, C.
    Liberati, A. M.
    Caravita, T.
    Petrucci, M. T.
    Palumbo, A.
    Musto, P.
    Sonneveld, P.
    Boccadoro, M.
    HAEMATOLOGICA, 2019, 104 : 69 - 70
  • [32] Overexpression of Mir-21-5p Induces Apoptosis and Cell Cycle Arrest By Down-Regulating SKP2 and Overcomes Bortezomib Resistance in Multiple Myeloma
    William, Jonahunnatha Nesson George
    Wu, Jian
    Chen, Ziyan
    Faruq, Omar
    Chang, Hong
    BLOOD, 2019, 134
  • [33] Real Life, Retrospective Analysis of Bortezomib Re-Use As Second Treatment for Relapsed Multiple Myeloma Patients Previously Exposed to Bortezomib-Based Therapies As First Line: The Rebound Study
    Musto, Pellegrino
    Simeon, Vittorio
    Cascavilla, Nicola
    Falcone, Antonietta
    Petrucci, Maria Teresa
    Cesini, Laura
    Di Raimondo, Francesco
    Conticello, Concetta
    Ria, Roberto
    Catalano, Lucio
    Salvatore, Dalila
    Mastrullo, Lucia
    Gagliardi, Alfredo
    Villani, Oreste
    Pietrantuono, Giuseppe
    D'Arena, Giovanni
    Mansueto, Giovanna
    Patriarca, Andrea
    Bringhen, Sara
    Genuardi, Mariella
    Di Renzo, Nicola
    Reddiconto, Giovanni
    Fragasso, Alberto
    Caravita, Tommaso
    Mangiacavalli, Silvia
    Palumbo, Antonio
    Corso, Alessandro
    BLOOD, 2016, 128 (22)
  • [34] Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the REBOUND Study)
    Pellegrino Musto
    Vittorio Simeon
    Nicola Cascavilla
    Antonietta Falcone
    Maria Teresa Petrucci
    Laura Cesini
    Francesco Di Raimondo
    Concetta Conticello
    Roberto Ria
    Lucio Catalano
    Dalila Salvatore
    Lucia Mastrullo
    Alfredo Gagliardi
    Oreste Villani
    Giuseppe Pietrantuono
    Giovanni D’Arena
    Giovanna Mansueto
    Sara Bringhen
    Mariella Genuardi
    Nicola Di Renzo
    Giovanni Reddiconto
    Alberto Fragasso
    Tommaso Caravita
    Daniele Scapicchio
    Gioacchino Marziano
    Mario Boccadoro
    Silvia Mangiacavalli
    Alessandro Corso
    Annals of Hematology, 2019, 98 : 361 - 367
  • [35] Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the REBOUND Study)
    Musto, Pellegrino
    Simeon, Vittorio
    Cascavilla, Nicola
    Falcone, Antonietta
    Petrucci, Maria Teresa
    Cesini, Laura
    Di Raimondo, Francesco
    Conticello, Concetta
    Ria, Roberto
    Catalano, Lucio
    Salvatore, Dalila
    Mastrullo, Lucia
    Gagliardi, Alfredo
    Villani, Oreste
    Pietrantuono, Giuseppe
    D'Arena, Giovanni
    Mansueto, Giovanna
    Bringhen, Sara
    Genuardi, Mariella
    Di Renzo, Nicola
    Reddiconto, Giovanni
    Fragasso, Alberto
    Caravita, Tommaso
    Scapicchio, Daniele
    Marziano, Gioacchino
    Boccadoro, Mario
    Mangiacavalli, Silvia
    Corso, Alessandro
    ANNALS OF HEMATOLOGY, 2019, 98 (02) : 361 - 367
  • [36] SNP rs34172460 (S258A)(A)over-cap in Gene CIP2A Correlates with Bortezomib Resistance in Multiple Myeloma Patients
    Tang, George
    Li, Mingjie
    Sanchez, Eric
    Wang, Cathy
    Vardanyan, Suzie
    Lee, Tiffany
    Nosrati, Jason
    Cao, Jasmin
    Zahab, Michael
    Mehta, Puja
    Garzio, Gigi
    Chen, Haiming
    Berenson, James
    BLOOD, 2015, 126 (23)
  • [37] The Relationship of CCL5 and CCR1 Variants with Response Rate and Survival Taking into Account Thalidomide/Bortezomib Treatment in Patients with Multiple Myeloma
    Popek-Marciniec, Sylwia
    Styk, Wojciech
    Wojcierowska-Litwin, Magdalena
    Szudy-Szczyrek, Aneta
    Dudek, Paul
    Swiderska-Kolacz, Grazyna
    Czerwik-Marcinkowska, Joanna
    Zmorzynski, Szymon
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (06)
  • [38] Single nucleotide polymorphisms in the promoter region of the IL1B gene influence outcome in multiple myeloma patients treated with high-dose chemotherapy independently of relapse treatment with thalidomide and bortezomib
    Vangsted, Annette J.
    Klausen, Tobias W.
    Abildgaard, Niels
    Andersen, Niels F.
    Gimsing, Peter
    Gregersen, Henrik
    Nexo, Bjorn A.
    Vogel, Ulla
    ANNALS OF HEMATOLOGY, 2011, 90 (10) : 1173 - 1181
  • [39] Single nucleotide polymorphisms in the promoter region of the IL1B gene influence outcome in multiple myeloma patients treated with high-dose chemotherapy independently of relapse treatment with thalidomide and bortezomib
    Annette J. Vangsted
    Tobias W. Klausen
    Niels Abildgaard
    Niels F. Andersen
    Peter Gimsing
    Henrik Gregersen
    Bjørn A. Nexø
    Ulla Vogel
    Annals of Hematology, 2011, 90 : 1173 - 1181
  • [40] REAL-WORLD USAGE OF BORTEZOMIB IN COMBINATION WITH THALIDOMIDE AND DEXAMETHASONE (VTD) AS FRONTLINE (FL) TREATMENT IN STEM CELL TRANSPLANT (SCT) ELIGIBLE MULTIPLE MYELOMA (MM) PATIENTS ACROSS EU5 COUNTRIES
    Anjo, J.
    Rider, A.
    Bailey, A.
    Gaudig, M.
    VALUE IN HEALTH, 2018, 21 : S70 - S70
12345